We are live on
!
Find out more
FCMI
Foresite Capital Management IV Portfolio holdings
AUM
$237M
1-Year Est. Return
107.53%
This Fund
S&P 500
This Quarter
Est. Return
+26.71%
1 Year Est. Return
+107.53%
3 Year Est. Return
+149.4%
5 Year Est. Return
+13.8%
10 Year Est. Return
–
AUM
$293M
AUM Growth
+$52.2M
(+22%)
Cap. Flow
+$3.78M
Cap. Flow
% of AUM
1.29%
Top 10 Holdings %
Top 10 Hldgs %
90.12%
Holding
21
New
3
Increased
8
Reduced
5
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rhythm Pharmaceuticals
RYTM
|
+$14.3M |
| 2 |
OPTN
OptiNose
OPTN
|
+$10M |
| 3 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$8.41M |
| 4 |
Arbutus Biopharma
ABUS
|
+$6.94M |
| 5 |
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
|
+$5.14M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
uniQure
QURE
|
+$17.6M |
| 2 |
Ascendis Pharma A/S
ASND
|
+$13.5M |
| 3 |
Arcus Biosciences
RCUS
|
+$5.57M |
| 4 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
+$2.39M |
| 5 |
CBAY
Cymabay Therapeutics
CBAY
|
+$1.11M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Insmed
INSM
$21.4B
| $42.6M | 14.52% |
1,800,587
+1,362
| +0.1% | +$35.1K |
|
|
BHVN
2
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $33.6M | 11.47% |
851,200
| – | – |
|
|
IMMU
3
DELISTED
Immunomedics Inc
IMMU
| $29.2M | 9.94% |
1,231,543
+158,271
| +15% | +$3.18M |
|
|
MYOK
4
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $28.1M | 9.58% |
565,755
+173,800
| +44% | +$8.41M |
|
|
CBAY
5
DELISTED
Cymabay Therapeutics
CBAY
| $27.2M | 9.26% |
2,023,369
-88,500
| -4% | -$1.11M |
|
|
OPTN
6
DELISTED
OptiNose
OPTN
| $26M | 8.86% |
61,903
+29,663
| +92% | +$10M |
|
|
7
Rhythm Pharmaceuticals
RYTM
$6.81B
| $22.6M | 7.69% |
721,903
+521,903
| +261% | +$14.3M |
|
|
8
Arbutus Biopharma
ABUS
$857M
| $19.4M | 6.6% |
2,651,825
+1,166,580
| +79% | +$6.94M |
|
|
9
Ascendis Pharma A/S
ASND
$16B
| $18M | 6.13% |
270,424
-204,995
| -43% | -$13.5M |
|
|
ALDR
10
DELISTED
Alder Biopharmaceuticals
ALDR
| $17.9M | 6.09% |
1,130,919
+300,000
| +36% | +$4.56M |
|
11
Aclaris Therapeutics
ACRS
$726M
| $10.6M | 3.6% |
529,551
+100,000
| +23% | +$1.85M |
|
|
ALDR
12
PUT
DELISTED
Alder Biopharmaceuticals
ALDR
| $5.53M | 1.89% |
350,000
-100,000
| -22% | -$1.52M |
|
|
EIDX
13
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $4.99M | 1.7% |
+245,082
| New | +$5.14M |
|
|
14
Arcus Biosciences
RCUS
$3.55B
| $3.61M | 1.23% |
295,000
-355,000
| -55% | -$5.57M |
|
|
TCDA
15
DELISTED
Tricida, Inc. Common Stock
TCDA
| $2.24M | 0.76% |
+75,000
| New | +$2.1M |
|
16
Kiniksa Pharmaceuticals
KNSA
$5.8B
| $1.64M | 0.56% |
+94,477
| New | +$1.71M |
|
|
17
uniQure
QURE
$3.03B
| $403K | 0.14% |
10,650
-549,423
| -98% | -$17.6M |
|
|
18
PUT
Insmed
INSM
$21.4B
| – | – |
-300,000
| Closed | -$6.8M |
|
19
Solid Biosciences
SLDB
$794M
| – | – |
-9,355
| Closed | -$1.05M |
|
|
MYOK
20
PUT
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| – | – |
-100,000
| Closed | -$4.9M |
|
|
RARX
21
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| – | – |
-450,000
| Closed | -$2.39M |
|
Similar funds
BCM
AG
FL
PVM
MFA
TCM
WW
CB
Foresite Capital Management IV's Q2 2018 Portfolio in Review
As of Q2 2018, Foresite Capital Management IV held 21 positions worth $293M, up 22% from $241M the previous quarter. Its ten largest holdings account for 90% of the portfolio.
Foresite Capital Management IV's Q2 2018 filing shows 3 new, 8 increased, 5 reduced and 4 closed positions. Its largest new stake was Eidos Therapeutics, Inc. Common Stock: 245,082 shares worth $4.99M. The largest sale was uniQure, an estimated $17.6M.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 85% a quarter earlier.
- Foresite Capital Management IV's largest Q2 2018 buy was Eidos Therapeutics, Inc. Common Stock: 245,082 shares worth $4.99M.
- Foresite Capital Management IV added most to Rhythm Pharmaceuticals in Q2 2018, an estimated $14.3M increase.
- Foresite Capital Management IV's biggest Q2 2018 reduction was uniQure, cutting an estimated $17.6M.
- Foresite Capital Management IV fully exited Ra Pharmaceuticals, Inc. Common Stock in Q2 2018, selling an estimated $2.39M.
- Foresite Capital Management IV's ten largest holdings make up 90% of its $293M portfolio in Q2 2018.
- Foresite Capital Management IV opened 3 new positions and closed 4 in Q2 2018.
- Foresite Capital Management IV's portfolio value rose 22% quarter-over-quarter to $293M.
Based on Foresite Capital Management IV's 13F filing for Q2 2018, filed 14 Aug 2018.